1.The mediating role of illness perception and illness distress on glycemic control and depression among people with type 2 diabetes
Tianyu ZHANG ; Ying XIANG ; Xuejia SONG ; Yanjie YANG ; Xiaohui QIU ; Ping LI
Chinese Journal of Behavioral Medicine and Brain Science 2020;29(7):620-623
Objective:To investigate the status of depression and physiological, psychological and social factors among people with type 2 diabetes(T2DM), as well as the mediating effects of illness perception and diabetes distress on glycemic control and depression.Methods:A total of 511 patients with type 2 diabetes were recruited and investigated using general demographic questionnaire, self-rating depression scale(SDS), brief illness perception questionnaire(BIPQ) and diabetes distress scale(DDS). Body mass index (BMI) and hemoglobin a1c (HbA1c) were detected in laboratory.Results:The mean score of SDS was (57.48±9.94). The distribution of depression condition were 138(27.0%)without depression, 179(35%)with mild depression, 174(34.1%)with moderate depression and 20(3.9%)with severe depression.SDS score was significantly positively correlated with poor glycemic control ( r=0.157, P<0.01), illness perception( r=0.359, P<0.01) and four dimensions of diabetes distress( r=0.177-0.354, P<0.01). Partially mediating effect of illness perception( B=0.216, 95% CI=0.112-0.372) was found in glycemic control and depression, the proportion of effect was 25.9%.The chain mediating effect ( B=0.086, 95% CI=0.042-0.149) of illness perception and diabetes distress was also found between glycemic control and depression, whose indirect effect size was 10.3%. Conclusion:Glycemic control is significantly related with depression.Illness perception and diabetes distress are partly mediating the effect between glycemic control and depression.
2.Meta-analysis of the Effects of Sh enqi Fuzheng Injection Combined with Conventional Chemotherapy on the Immune Function of Patients with Advanced NSCLC
Huizhen WU ; Xuejia QIU ; Zhanjun DONG ; Hongtao LIU
China Pharmacy 2019;30(22):3143-3149
OBJECTIVE: To systematically evaluate the effects of Shenqi fuzheng injection combined with conventional chemotherapy on the immune function of patients with advanced non-small cell lung cancer (NSCLC), and provide evidence-based reference for clinical medication. METHODS: Retrieved from Cochrane Library, PubMed, Medline, Embase, CNKI, Wanfang database, VIP and CBM, Shenqi fuzheng injection combined with conventional chemotherapy (trial group) versus conventional therapy (control group) for advanced NSCLC were collected. After literature screening, data extraction and quality evaluation with Cochrane system evaluator manual 5.1.0 risk evaluation tool, Meta-analysis was performed by using Rev Man 5.3 statistical software. RESULTS: A total of 16 literatures were included, involving 1 324 cases. Results of Meta-analysis showed that there were no statistical significance in the difference of objective remission rate (ORR) [RR=1.14, 95%CI(0.91,1.43), P=0.25] and the level of CD8+ [MD=-1.26,95%CI(-4.10, 1.59),P=0.39] between 2 groups. The levels of CD3+ [MD=17.48, 95%CI(13.40, 21.56), P<0.000 01 ], CD4+[MD=12.26, 95%CI(8.39 16.13), P<0.000 01], CD4+/CD8+ [MD=0.33,95%CI(0.27, 0.39),P<0.000 01] and the percentage of NK cells [MD=9.33, 95%CI(5.72, 12.94), P<0.000 01] in trial group were significantly higher than control group. Results of subgroup analysis for medication duration of Shenqi fuzheng injection showed that after 1-14 d treatment of Shenqi fuzheng injection, the levels of CD3+ [MD=17.11, 95%CI(12.37 ,23.17),P<0.000 01], CD4+[MD=13.28,95%CI(8.33, 18.23),P<0.000 01], CD4+/CD8+[MD=0.36,95%CI(0.28,0.43),P<0.000 01] and the percentage of NK cells [MD=12.06,95%CI(7.52,16.61),P<0.000 1] in trial group were significantly higher than control group. After 21 d treatment of Shenqi fuzheng injection, the levels of CD3+[MD=14.88, 95%CI(7.51,22.26),P<0.000 01], CD4+[MD=10.56,95%CI(5.57,15.56),P<0.000 01], CD8+[MD=3.02, 95%CI(1.80, 4.23),P<0.000 01], CD4+/CD8+[MD=0.29,95%CI(0.23, 0.35),P<0.000 01] and the percentage of NK cells [MD=5.58,95%CI(2.49, 8.67),P=0.000 4] in trial group were significantly higher than control group. There was no statistical significance in the level of CD8+ between 2 groups after 7-14 d treatment of Shenqi fuzheng injection [MD=-4.26,95%CI(-12.60, 4.09),P=0.32]. The incidence of leukopenia, nausea and vomiting, and renal dysfunction in trial group were significantly lower than control group. There was no statistical significance in the incidence of hemoglobin decreased and thrombocytopenia between 2 groups. The results of publication bias showed that there was a greater possibility of publication bias in this study. CONCLUSIONS: Shenqi fuzheng injection combined with conventional chemotherapy may improve the immune function of patients with advanced NSCLC and improve the safety after chemotherapy. But more large-scale, milltiple-center and high-quality RCT are needed to validate this conclusion.